Daraxonrasib: Experimental Oral Drug Could Transform Second-Line Cancer Treatment
As we continue to monitor advancements in oncology, a significant development has emerged regarding the treatment landscape for metastatic pancreatic ductal adenocarcinoma (PDAC). The U.S. Food and Drug Administration (FDA) has recently taken steps to facilitate access to an experimental therapy, daraxonrasib (also known as RMC-6236), which is currently under investigation for its potential to … Read more